Cleaved-Spectrin α II (D1185) Polyclonal Antibody
活动价:
市场价:¥880.00
- 50μL
- 100μL
FAB2600067
- 产品信息
商品描述
靶点-Target
Spectrin α II
反应性
Human,Rat,Mouse,
应用
WB,ELISA
宿主物种-Host Species
Rabbit
同种型-Isotype
IgG
修饰-Modification
Unmodified
MW(Observed)
137kD
推荐稀释比
WB 1:500-1:2000;ELISA 1:10000;Not yet tested in other applications.
组成
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
纯化工艺
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
储存
-15°C to -25°C/1 year(Do not lower than -25°C)
浓度
1 mg/ml
克隆性
Polyclonal
免疫原
The antiserum was produced against synthesized peptide derived from human SPTA2. AA range:1136-1185
特异性
Cleaved-Spectrin α II (D1185) Polyclonal Antibody detects endogenous levels of fragment of activated Spectrin α II protein resulting from cleavage adjacent to D1185.
基因名称
SPTAN1
蛋白名称
Spectrin alpha chain non-erythrocytic 1
别名
SPTAN1;NEAS;SPTA2;Spectrin alpha chain;non-erythrocytic 1;Alpha-II spectrin;Fodrin alpha chain;Spectrin, non-erythroid alpha subunit
Organism-1
Human
基因ID-1
6709
SwissProt-1
Q13813
Organism-2
Mouse
SwissProt-2
P16546
背景
Spectrins are a family of filamentous cytoskeletal proteins that function as essential scaffold proteins that stabilize the plasma membrane and organize intracellular organelles. Spectrins are composed of alpha and beta dimers that associate to form tetramers linked in a head-to-head arrangement. This gene encodes an alpha spectrin that is specifically expressed in nonerythrocytic cells. The encoded protein has been implicated in other cellular functions including DNA repair and cell cycle regulation. Mutations in this gene are the cause of early infantile epileptic encephalopathy-5. Alternate splicing results in multiple transcript variants.[provided by RefSeq, Sep 2010],
细胞定位
Cytoplasm, cytoskeleton. Cytoplasm, cell cortex. Expressed along the cell membrane in podocytes and presumptive tubule cells during glomerulogenesis and is expressed along lateral cell margins in tubule cells. .





